JOP20170192A1 - داي نوكليوتيد حلقي - Google Patents
داي نوكليوتيد حلقيInfo
- Publication number
- JOP20170192A1 JOP20170192A1 JOP/2017/0192A JOP20170192A JOP20170192A1 JO P20170192 A1 JOP20170192 A1 JO P20170192A1 JO P20170192 A JOP20170192 A JO P20170192A JO P20170192 A1 JOP20170192 A1 JO P20170192A1
- Authority
- JO
- Jordan
- Prior art keywords
- cyclic dinucleotide
- present disclosure
- sting
- compound
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Abstract
يوفر الكشف الحالي مركب ذي نشاط مساعد STING، المتوقع أن يكون مفيد كعامل للوقاية من أو علاج أمراض مرتبطة بـ STING. يتعلق الكشف الحالي بمركب تم التعبير عنه بواسطة الصيغة (I): حيث يكون كل رمز كما تم الوصف في المواصفات، أو ملح منه.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016234553 | 2016-12-01 | ||
JP2017107216A JP2018090562A (ja) | 2016-12-01 | 2017-05-30 | 環状ジヌクレオチド |
US201762589300P | 2017-11-21 | 2017-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20170192A1 true JOP20170192A1 (ar) | 2019-01-30 |
Family
ID=66179467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0192A JOP20170192A1 (ar) | 2016-12-01 | 2016-12-01 | داي نوكليوتيد حلقي |
Country Status (31)
Country | Link |
---|---|
US (3) | US10980825B2 (ar) |
EP (2) | EP3512861B1 (ar) |
JP (2) | JP6633255B1 (ar) |
KR (1) | KR102640802B1 (ar) |
CN (1) | CN110325543B (ar) |
AU (1) | AU2017370004B2 (ar) |
BR (1) | BR112019011120A2 (ar) |
CA (1) | CA3045762A1 (ar) |
CL (1) | CL2019001485A1 (ar) |
CO (1) | CO2019007032A2 (ar) |
CY (1) | CY1124196T1 (ar) |
DK (1) | DK3512861T3 (ar) |
EC (1) | ECSP19046507A (ar) |
ES (1) | ES2866948T3 (ar) |
HR (1) | HRP20210726T1 (ar) |
HU (1) | HUE054450T2 (ar) |
IL (1) | IL267020B (ar) |
JO (1) | JOP20170192A1 (ar) |
LT (1) | LT3512861T (ar) |
MA (1) | MA46245A (ar) |
MX (1) | MX2019006397A (ar) |
MY (1) | MY190460A (ar) |
PE (1) | PE20210255A1 (ar) |
PH (1) | PH12019501222A1 (ar) |
PL (1) | PL3512861T3 (ar) |
PT (1) | PT3512861T (ar) |
RS (1) | RS61818B1 (ar) |
SI (1) | SI3512861T1 (ar) |
UA (1) | UA126390C2 (ar) |
WO (1) | WO2018100558A2 (ar) |
ZA (1) | ZA201904311B (ar) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
HRP20221263T1 (hr) | 2016-03-18 | 2023-03-03 | Immune Sensor, Llc | Ciklički di-nukleotidni spojevi i postupci uporabe |
US11033569B2 (en) | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
CA3040143A1 (en) | 2016-10-14 | 2018-04-19 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
EP3558324A4 (en) * | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT |
WO2018138685A2 (en) * | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
PE20210156A1 (es) | 2017-11-10 | 2021-01-26 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso |
WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
EP3727401A4 (en) * | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS |
EP3505188A1 (en) | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
TW202003032A (zh) | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含s t i n g 促效劑之胞外囊泡 |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
EP3848054A4 (en) | 2018-09-06 | 2022-06-01 | Daiichi Sankyo Company, Limited | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF |
CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
JP7218431B2 (ja) | 2018-09-21 | 2023-02-06 | シャンハイ ドーァ ノボ ファーマテック カンパニー,リミティド | 環状ジヌクレオチド類似体、その医薬組成物及び使用 |
JP2022502431A (ja) | 2018-09-27 | 2022-01-11 | ピエール、ファーブル、メディカマン | スルホマレイミドに基づくリンカーおよび対応する複合体 |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020191377A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
WO2020191369A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
AU2020240135A1 (en) | 2019-03-21 | 2021-10-14 | Lonza Sales Ag | Extracellular vesicles for vaccine delivery |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
JP2022531899A (ja) | 2019-05-09 | 2022-07-12 | アリゴス セラピューティクス インコーポレイテッド | Stingモジュレータとしての修飾環状ジヌクレオシド化合物 |
KR20220006519A (ko) | 2019-05-10 | 2022-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 항체 약물 접합체 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
US20220257630A1 (en) * | 2019-07-09 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Administration of sting agonist and checkpoint inhibitors |
TW202116358A (zh) | 2019-07-19 | 2021-05-01 | 美商免疫感應治療公司 | 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途 |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
WO2021062058A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
EP4034276A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
KR20220094221A (ko) | 2019-09-25 | 2022-07-05 | 코디악 바이오사이언시즈, 인크. | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 |
EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
PE20221111A1 (es) | 2019-09-30 | 2022-07-11 | Gilead Sciences Inc | Vacunas para vhb y metodos de tratamiento de vhb |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
MX2022009597A (es) | 2020-03-06 | 2022-09-02 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso. |
WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
EP4121450A2 (en) | 2020-03-20 | 2023-01-25 | Codiak BioSciences, Inc. | Extracellular vesicles for therapy |
KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
AU2021295292A1 (en) * | 2020-06-24 | 2023-02-16 | Sapreme Technologies B.V. | Saponin derivatives for use in medicine |
EP4171645A2 (en) * | 2020-06-24 | 2023-05-03 | Sapreme Technologies B.V. | Hydrazone-based saponin derivatives |
JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ,インク. | 抗asgr1抗体コンジュゲートおよびその使用 |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2022050300A1 (ja) | 2020-09-02 | 2022-03-10 | 第一三共株式会社 | 新規エンド-β-N-アセチルグルコサミニダーゼ |
JP2023546316A (ja) * | 2020-09-08 | 2023-11-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 多価sting活性化組成物およびその使用法 |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
CA3192470A1 (en) | 2020-09-23 | 2022-03-31 | Tim SOOS | Methods of producing extracellular vesicles |
CA3193107A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
KR102558127B1 (ko) * | 2020-10-23 | 2023-07-24 | 아주대학교산학협력단 | 아릴피페라진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
TW202233206A (zh) | 2020-11-18 | 2022-09-01 | 日商武田藥品工業股份有限公司 | Sting促效劑、檢查點抑制劑及輻射之投與 |
KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US20230046340A1 (en) | 2021-06-23 | 2023-02-16 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4137499A1 (en) | 2021-08-17 | 2023-02-22 | Ustav organicke chemie a biochemie AV CR, v.v.i. | 7-substituted 7-deazaadenine-containing 2,3 -cyclic dinucleotides |
WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL90359A0 (en) | 1988-05-26 | 1989-12-15 | University Patents Inc | Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production |
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
EP1645561A1 (en) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
US8367716B2 (en) | 2003-07-28 | 2013-02-05 | Karaolis David K R | Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
WO2006078278A2 (en) | 2004-04-27 | 2006-07-27 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
US20090012038A1 (en) | 2004-10-18 | 2009-01-08 | Spormann Alfred M | Methods for microbial biofilm destruction and interference with microbial cellular physiology |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
EA201792376A3 (ru) * | 2009-10-23 | 2018-08-31 | Милленниум Фармасьютикалз, Инк. | Молекулы анти-gcc антитела и соответствующие композиции и способы |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
EP3301177B1 (en) | 2011-11-18 | 2020-03-25 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
SG11201502796RA (en) * | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
PL2934598T3 (pl) | 2012-12-19 | 2018-10-31 | Board Of Regents, The University Of Texas System | Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy |
JP6153116B2 (ja) | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
PE20160167A1 (es) * | 2013-04-29 | 2016-04-21 | Sloan Kettering Inst Cancer | Composiciones y metodos para alterar la senalizacion del segundo mensajero |
EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
US9549944B2 (en) * | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
US9724408B2 (en) | 2013-05-18 | 2017-08-08 | Aduro Biotech, Inc. | Compositions and methods for activating stimulator of interferon gene-dependent signalling |
US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
EP3071209A4 (en) * | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
SG11201609021QA (en) | 2014-06-04 | 2016-11-29 | Glaxosmithkline Ip Dev Ltd | Cyclic di-nucleotides as modulators of sting |
US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
EP3546473A1 (en) * | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
WO2016102204A1 (en) * | 2014-12-22 | 2016-06-30 | Basf Se | Use of a chemical mechanical polishing (cmp) composition for polishing of cobalt and / or cobalt alloy comprising substrates |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN107530415A (zh) | 2015-03-10 | 2018-01-02 | 艾杜罗生物科技公司 | 用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
FR3037784B1 (fr) * | 2015-06-29 | 2017-12-15 | Gexfix Sa | Dispositif de fixation externe dynamique d'osteosynthese |
WO2017011444A1 (en) | 2015-07-13 | 2017-01-19 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating b cell cancers |
TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導rig-i和其他模式辨識受體之化合物及組成物 |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
KR102271750B1 (ko) | 2015-08-13 | 2021-06-30 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
WO2017075477A1 (en) | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
US20170146519A1 (en) | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
US20180369268A1 (en) | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
WO2017123669A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
HRP20221263T1 (hr) * | 2016-03-18 | 2023-03-03 | Immune Sensor, Llc | Ciklički di-nukleotidni spojevi i postupci uporabe |
WO2017165506A1 (en) | 2016-03-23 | 2017-09-28 | Academia Sinica | Thin-shell polymeric nanoparticles and uses thereof |
HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
EP3448393A1 (en) | 2016-04-25 | 2019-03-06 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
US11033569B2 (en) | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
WO2018009652A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
CN109715202A (zh) | 2016-07-15 | 2019-05-03 | 斯必乐维生物科学公司 | 用于治疗疾病的化合物、组合物和方法 |
WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
EP3523314A1 (de) | 2016-10-07 | 2019-08-14 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
EP3558324A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT |
EP3558358A4 (en) | 2016-12-20 | 2020-09-30 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUKLEOTIDE STING AGONISTS FOR CANCER TREATMENT |
WO2018119117A1 (en) | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Methods of producing cyclic dinucleotides |
EP3574018A4 (en) | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
WO2018138685A2 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
CN110234404A (zh) | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
CN106667914B (zh) | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
CN111032672A (zh) | 2017-08-31 | 2020-04-17 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
JP7208225B2 (ja) | 2017-08-31 | 2023-01-18 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
WO2019055750A1 (en) | 2017-09-15 | 2019-03-21 | Aduro Biotech, Inc. | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF |
PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
-
2016
- 2016-12-01 JO JOP/2017/0192A patent/JOP20170192A1/ar unknown
-
2017
- 2017-12-01 MY MYPI2019003124A patent/MY190460A/en unknown
- 2017-12-01 RS RS20210562A patent/RS61818B1/sr unknown
- 2017-12-01 CA CA3045762A patent/CA3045762A1/en active Pending
- 2017-12-01 AU AU2017370004A patent/AU2017370004B2/en active Active
- 2017-12-01 UA UAA201907162A patent/UA126390C2/uk unknown
- 2017-12-01 KR KR1020197019077A patent/KR102640802B1/ko active IP Right Grant
- 2017-12-01 PL PL17817176T patent/PL3512861T3/pl unknown
- 2017-12-01 EP EP17817176.5A patent/EP3512861B1/en active Active
- 2017-12-01 DK DK17817176.5T patent/DK3512861T3/da active
- 2017-12-01 HU HUE17817176A patent/HUE054450T2/hu unknown
- 2017-12-01 WO PCT/IB2017/057588 patent/WO2018100558A2/en active Application Filing
- 2017-12-01 CN CN201780074714.9A patent/CN110325543B/zh active Active
- 2017-12-01 JP JP2019527462A patent/JP6633255B1/ja active Active
- 2017-12-01 MA MA046245A patent/MA46245A/fr unknown
- 2017-12-01 ES ES17817176T patent/ES2866948T3/es active Active
- 2017-12-01 MX MX2019006397A patent/MX2019006397A/es unknown
- 2017-12-01 PE PE2019001164A patent/PE20210255A1/es unknown
- 2017-12-01 BR BR112019011120A patent/BR112019011120A2/pt unknown
- 2017-12-01 LT LTEP17817176.5T patent/LT3512861T/lt unknown
- 2017-12-01 PT PT178171765T patent/PT3512861T/pt unknown
- 2017-12-01 SI SI201730756T patent/SI3512861T1/sl unknown
- 2017-12-01 EP EP21157239.1A patent/EP3868384A1/en active Pending
-
2018
- 2018-11-09 US US16/185,258 patent/US10980825B2/en active Active
-
2019
- 2019-05-30 IL IL267020A patent/IL267020B/en unknown
- 2019-05-31 PH PH12019501222A patent/PH12019501222A1/en unknown
- 2019-05-31 CL CL2019001485A patent/CL2019001485A1/es unknown
- 2019-06-28 CO CONC2019/0007032A patent/CO2019007032A2/es unknown
- 2019-06-28 ZA ZA2019/04311A patent/ZA201904311B/en unknown
- 2019-06-28 EC ECSENADI201946507A patent/ECSP19046507A/es unknown
- 2019-12-11 JP JP2019223919A patent/JP7229907B2/ja active Active
-
2020
- 2020-10-07 US US17/065,242 patent/US11666594B2/en active Active
-
2021
- 2021-05-06 CY CY20211100384T patent/CY1124196T1/el unknown
- 2021-05-10 HR HRP20210726TT patent/HRP20210726T1/hr unknown
-
2023
- 2023-05-01 US US18/310,467 patent/US20240066047A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20170192A1 (ar) | داي نوكليوتيد حلقي | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
PH12017502363A1 (en) | Brk inhibitory compound | |
PH12016501614A1 (en) | Heterocyclic compound | |
PH12016500225B1 (en) | Novel quinoline-substituted compound | |
TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
JO3472B1 (ar) | مركبات ديهايدروبنزوفوران مفيدة في علاج السكري والسمنة | |
EA201990833A1 (ru) | Соединение пиридина | |
EA201390794A1 (ru) | Бициклическое соединение | |
BR112017011422A2 (pt) | compostos de ácido isoazol hidro¬xâmico como inibidores de lpxc | |
PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
PH12019502248A1 (en) | Ip6k inhibitors | |
EA201692063A1 (ru) | Спиросоединения мочевины в качестве противовирусных соединений против rsv | |
TN2017000097A1 (en) | Heterocyclic compound | |
UY37502A (es) | Dinucleótido cíclico | |
MY191759A (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
EA201401277A1 (ru) | Соединения метантиона, обладающие противовирусной активностью | |
GEP20156399B (en) | Microbiocidal heterocycles | |
NZ715554A (en) | Method of treating hypertrophic cardiomyopathy | |
EA201991315A1 (ru) | Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона) | |
MX2021003481A (es) | Compuesto heterociclico. | |
TN2013000230A1 (en) | Bicyclic compound |